Nevro Corp. Company Profile (NYSE:NVRO)

About Nevro Corp. (NYSE:NVRO)

Nevro Corp. logoNevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:NVRO
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.5534 billion
  • Outstanding Shares: 29,296,000
Average Prices:
  • 50 Day Moving Avg: $76.63
  • 200 Day Moving Avg: $85.14
  • 52 Week Range: $65.82 - $106.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2,895.33
  • P/E Growth: -3.37
Sales & Book Value:
  • Annual Revenue: $255.29 million
  • Price / Sales: 9.97
  • Book Value: $8.29 per share
  • Price / Book: 10.48
  • EBIDTA: ($25,290,000.00)
  • Net Margins: -14.49%
  • Return on Equity: -14.50%
  • Return on Assets: -8.50%
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 11.91%
  • Quick Ratio: 9.43%
  • Average Volume: 790,102 shs.
  • Beta: -0.73
  • Short Ratio: 5.32

Frequently Asked Questions for Nevro Corp. (NYSE:NVRO)

What is Nevro Corp.'s stock symbol?

Nevro Corp. trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro Corp.'s earnings last quarter?

Nevro Corp. (NYSE:NVRO) released its earnings results on Monday, May, 8th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.24. The business had revenue of $68.40 million for the quarter, compared to analyst estimates of $68.71 million. Nevro Corp. had a negative return on equity of 14.50% and a negative net margin of 14.49%. Nevro Corp.'s revenue was up 64.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.33) EPS. View Nevro Corp.'s Earnings History.

Where is Nevro Corp.'s stock going? Where will Nevro Corp.'s stock price be in 2017?

9 analysts have issued 1-year price objectives for Nevro Corp.'s stock. Their forecasts range from $85.00 to $120.00. On average, they anticipate Nevro Corp.'s stock price to reach $103.89 in the next year. View Analyst Ratings for Nevro Corp..

What are analysts saying about Nevro Corp. stock?

Here are some recent quotes from research analysts about Nevro Corp. stock:

  • 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (6/3/2017)
  • 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)

Who are some of Nevro Corp.'s key competitors?

Who are Nevro Corp.'s key executives?

Nevro Corp.'s management team includes the folowing people:

  • Rami Elghandour, President, Chief Executive Officer
  • Andrew H. Galligan, Chief Financial Officer
  • Patrick Schmitz, Vice President - Operations
  • Michael Enxing, Vice President of Sales
  • Douglas A. Alleavitch, Vice President - Quality and Operations
  • Christopher Christoforou, Vice President - Research and Development
  • Ali Behbahani M.D., Independent Director
  • Lisa D. Earnhardt, Independent Director
  • Frank M. Fischer, Independent Director
  • Wilfred E. Jaeger M.D., Independent Director

Who owns Nevro Corp. stock?

Nevro Corp.'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.11%), Bank of Montreal Can (0.05%), Gradient Investments LLC (0.01%), Inspirion Wealth Advisors LLC (0.01%), US Bancorp DE (0.01%) and Creative Planning (0.01%). Company insiders that own Nevro Corp. stock include Andre Walker, Andrew H Galligan, Brad Vale, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro Corp..

Who sold Nevro Corp. stock? Who is selling Nevro Corp. stock?

Nevro Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have sold Nevro Corp. stock in the last year include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Insider Buying and Selling for Nevro Corp..

Who bought Nevro Corp. stock? Who is buying Nevro Corp. stock?

Nevro Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Gradient Investments LLC, Bank of Montreal Can, Inspirion Wealth Advisors LLC and US Bancorp DE. View Insider Buying and Selling for Nevro Corp..

How do I buy Nevro Corp. stock?

Shares of Nevro Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro Corp.'s stock price today?

One share of Nevro Corp. stock can currently be purchased for approximately $86.86.

MarketBeat Community Rating for Nevro Corp. (NYSE NVRO)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Nevro Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nevro Corp. (NYSE:NVRO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $103.89 (19.60% upside)

Analysts' Ratings History for Nevro Corp. (NYSE:NVRO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/5/2017Canaccord GenuityReiterated RatingBuy$120.00HighView Rating Details
7/3/2017J P Morgan Chase & CoReiterated RatingOverweight$102.00LowView Rating Details
6/15/2017Northland SecuritiesSet Price TargetBuy$96.00LowView Rating Details
5/14/2017B. RileyDowngradeNeutral$85.00LowView Rating Details
2/24/2017Leerink SwannBoost Price TargetOutperform$100.00 -> $110.00N/AView Rating Details
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 -> $112.00N/AView Rating Details
8/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$90.00 -> $110.00N/AView Rating Details
8/9/2016BMO Capital MarketsReiterated RatingBuy$100.00N/AView Rating Details
8/8/2016Bank of America CorporationInitiated CoverageBuy$100.00N/AView Rating Details
7/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
7/12/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
6/29/2016Morgan StanleyReiterated RatingBuy$86.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for Nevro Corp. (NYSE:NVRO)
Earnings by Quarter for Nevro Corp. (NYSE:NVRO)
Earnings History by Quarter for Nevro Corp. (NYSE NVRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.26)($0.50)$68.71 million$68.40 millionViewListenView Earnings Details
2/23/2017Q416($0.20)($0.34)$66.41 million$70.50 millionViewN/AView Earnings Details
11/7/2016Q316($0.39)($0.14)$58.05 million$60.92 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.31)$45.11 million$55.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.65)($0.33)$33.48 million$41.65 millionViewN/AView Earnings Details
2/29/2016Q415($0.56)($0.51)$32.88 million$33.10 millionViewListenView Earnings Details
11/9/2015Q315($0.75)($0.70)$12.51 million$15.40 millionViewN/AView Earnings Details
8/6/2015Q215($0.89)($0.77)$9.65 million$11.40 millionViewN/AView Earnings Details
5/11/2015Q1($0.54)($0.57)$8.20 million$9.66 millionViewListenView Earnings Details
3/18/2015Q4 2014($0.51)($0.59)$9.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nevro Corp. (NYSE:NVRO)
Current Year EPS Consensus Estimate: $-1.02 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS


Dividend History for Nevro Corp. (NYSE:NVRO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Nevro Corp. (NYSE:NVRO)
Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro Corp. (NYSE:NVRO)
Institutional Ownership by Quarter for Nevro Corp. (NYSE:NVRO)
Insider Trades by Quarter for Nevro Corp. (NYSE:NVRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Andrew H. GalliganCFOSell7,500$75.30$564,750.00View SEC Filing  
5/2/2017Michael F DemaneDirectorSell29,800$96.07$2,862,886.00View SEC Filing  
5/1/2017Rami ElghandourCEOSell10,000$95.03$950,300.00View SEC Filing  
4/4/2017Michael EnxingVPSell1,500$93.53$140,295.00View SEC Filing  
4/4/2017Michael F DemaneDirectorSell22,200$93.39$2,073,258.00View SEC Filing  
4/3/2017Andrew H. GalliganCFOSell30,000$94.46$2,833,800.00View SEC Filing  
3/6/2017Michael EnxingVPSell38,500$91.01$3,503,885.00View SEC Filing  
3/3/2017Wilfred E JaegerDirectorSell43,980$95.03$4,179,419.40View SEC Filing  
1/4/2017Michael EnxingVPSell1,500$75.88$113,820.00View SEC Filing  
12/5/2016Michael EnxingVPSell1,500$76.38$114,570.00View SEC Filing  
11/15/2016Andrew H GalliganCFOSell7,500$86.90$651,750.00View SEC Filing  
10/10/2016Rami ElghandourCEOSell3,000$100.00$300,000.00View SEC Filing  
10/6/2016Michael F DemaneDirectorSell139,514$97.46$13,597,034.44View SEC Filing  
10/4/2016Michael EnxingVPSell1,500$99.31$148,965.00View SEC Filing  
8/22/2016Doug AlleavitchVPSell3,000$100.00$300,000.00View SEC Filing  
8/22/2016Wilfred E JaegerDirectorSell154,840$97.79$15,141,803.60View SEC Filing  
8/17/2016Wilfred E JaegerDirectorSell155,160$97.31$15,098,619.60View SEC Filing  
8/15/2016Andrew H GalliganCFOSell7,500$97.71$732,825.00View SEC Filing  
8/10/2016Doug AlleavitchVPSell2,500$95.00$237,500.00View SEC Filing  
8/9/2016Michael F DemaneDirectorSell26,667$91.50$2,440,030.50View SEC Filing  
8/4/2016Michael EnxingVPSell1,500$82.06$123,090.00View SEC Filing  
7/29/2016Doug AlleavitchVPSell1,000$85.00$85,000.00View SEC Filing  
7/29/2016Michael F DemaneDirectorSell13,333$84.00$1,119,972.00View SEC Filing  
7/11/2016Doug AlleavitchVPSell2,000$80.00$160,000.00View SEC Filing  
7/11/2016Michael F DemaneDirectorSell13,333$79.00$1,053,307.00View SEC Filing  
7/5/2016Michael EnxingVPSell1,500$75.39$113,085.00View SEC Filing  
7/1/2016Michael F DemaneDirectorSell13,333$74.00$986,642.00View SEC Filing  
6/8/2016Doug AlleavitchVPSell1,000$75.00$75,000.00View SEC Filing  
6/8/2016Rami ElghandourCEOSell7,000$76.59$536,130.00View SEC Filing  
6/6/2016Michael EnxingVPSell1,500$73.29$109,935.00View SEC Filing  
6/2/2016Andre WalkerVPSell4,000$73.50$294,000.00View SEC Filing  
6/1/2016Doug AlleavitchVPSell500$72.00$36,000.00View SEC Filing  
5/18/2016Wilfred E JaegerDirectorSell112,983$64.68$7,307,740.44View SEC Filing  
5/16/2016Andrew H GalliganCFOSell10,000$64.78$647,800.00View SEC Filing  
5/16/2016Michael F DemaneCEOSell39,999$64.77$2,590,735.23View SEC Filing  
5/12/2016Rami ElghandourPresidentSell7,000$63.93$447,510.00View SEC Filing  
5/4/2016Michael EnxingVPSell1,500$65.06$97,590.00View SEC Filing  
4/4/2016Michael EnxingVPSell8,767$61.59$539,959.53View SEC Filing  
4/1/2016Rami ElghandourPresidentSell7,000$60.99$426,930.00View SEC Filing  
1/11/2016Andre WalkerVPSell7,987$70.75$565,080.25View SEC Filing  
1/4/2016Doug AlleavitchVPSell2,514$66.47$167,105.58View SEC Filing  
12/17/2015Andre WalkerVPSell13$69.00$897.00View SEC Filing  
12/7/2015Rami ElghandourPresidentSell3,500$61.82$216,370.00View SEC Filing  
12/2/2015Andre WalkerVPSell1,000$64.00$64,000.00View SEC Filing  
12/1/2015Andre WalkerVPSell8,000$59.50$476,000.00View SEC Filing  
11/30/2015Andre WalkerVPSell6,000$58.50$351,000.00View SEC Filing  
11/30/2015Rami ElghandourPresidentSell3,500$60.00$210,000.00View SEC Filing  
11/24/2015Andre WalkerVPSell1,000$55.00$55,000.00View SEC Filing  
11/23/2015Andre WalkerVPSell1,000$54.00$54,000.00View SEC Filing  
11/23/2015Wilfred E JaegerDirectorSell25,000$53.48$1,337,000.00View SEC Filing  
11/18/2015Wilfred E JaegerDirectorSell175,000$52.24$9,142,000.00View SEC Filing  
11/16/2015Michael F DemaneCEOSell26,667$50.52$1,347,216.84View SEC Filing  
11/13/2015Brad ValeDirectorBuy2,000$50.76$101,520.00View SEC Filing  
9/17/2015Andre WalkerVPSell4,000$50.75$203,000.00View SEC Filing  
9/2/2015Michael F DemaneCEOSell40,001$45.11$1,804,445.11View SEC Filing  
6/8/2015& Johnson JohnsonMajor ShareholderSell1,010,265$47.94$48,432,104.10View SEC Filing  
6/8/2015Bay City Capital LlcInsiderSell491,835$47.94$23,578,569.90View SEC Filing  
6/8/2015Wilfred E JaegerDirectorSell393,468$47.94$18,862,855.92View SEC Filing  
11/12/2014& Johnson JohnsonMajor ShareholderBuy40,000$18.00$720,000.00View SEC Filing  
11/12/2014A/S NovoInsiderBuy215,000$18.00$3,870,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Nevro Corp. (NYSE:NVRO)
Latest Headlines for Nevro Corp. (NYSE:NVRO)
DateHeadline logoNevro Corp. (NVRO) Upgraded to "Hold" at BidaskClub - July 16 at 10:50 PM logoNevro Corp (NVRO) Shares Cross Above 200 DMA - July 14 at 7:01 AM logoMedical Equipment Stock Performance Review -- Nevro, EnteroMedics, Avinger, and ViewRay - July 13 at 7:32 AM logoNevro (NVRO) Surges: Stock Moves 11.4% Higher - Nasdaq - July 8 at 6:13 PM logoETFs with exposure to Nevro Corp. : July 7, 2017 - July 8 at 1:12 PM logoNevro Corp. breached its 50 day moving average in a Bullish Manner : NVRO-US : July 6, 2017 - July 7 at 7:47 AM logoHealth Care Sector Update for 07/05/2017: NVRO,MTBC,BGNE - Nasdaq - July 6 at 7:36 AM logoBUZZ-U.S. STOCKS ON THE MOVE- Tesla, Diebold Nixdorf, Nevro ... - Nasdaq - July 6 at 7:36 AM logoHere's Why Shares of Nevro Corp. (NVRO) Jumped Today - Nasdaq - July 6 at 7:36 AM logoHere's Why Shares of Nevro Corp. (NVRO) Jumped Today - July 6 at 7:36 AM logo Brokerages Anticipate Nevro Corp. (NVRO) Will Post Earnings of -$0.29 Per Share - July 5 at 2:12 PM logoCanaccord Genuity Reaffirms Buy Rating for Nevro Corp. (NYSE:NVRO) - July 5 at 1:58 PM logoWhy Nevro Corp. Is Soaring 10% Higher Today - July 5 at 1:19 PM logoNevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update - PR Newswire (press release) - July 5 at 9:03 AM logoNevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update - July 5 at 9:03 AM logoNevro Corp. (NYSE:NVRO) Given Average Recommendation of "Buy" by Brokerages - July 3 at 10:40 AM logoNevro Corp. (NYSE:NVRO) Stock Rating Reaffirmed by J P Morgan Chase & Co - July 3 at 9:50 AM logoETFs with exposure to Nevro Corp. : June 26, 2017 - June 27 at 6:47 AM logoNevro Corp. (NVRO) Given a $96.00 Price Target at Northland Securities - June 17 at 2:20 PM logoETFs with exposure to Nevro Corp. : June 16, 2017 - June 16 at 7:55 PM logoNevro (NVRO) SENZA-RCT 24-Month Outcomes Publication Selected by Neurosurgery as Top Pain Paper of the Year - - June 16 at 8:20 AM logoNeurosurgery Selects the SENZA-RCT 24-Month Outcomes Publication as the Top Pain Paper of the Year - June 16 at 8:20 AM logoNevro Corp. :NVRO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 4:10 PM logo Brokerages Expect Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million - June 11 at 8:56 AM logoZacks: Brokerages Anticipate Nevro Corp (NVRO) Will Post Earnings of -$0.29 Per Share - June 9 at 2:12 PM logoNevro Corp (NVRO) Receives Average Rating of "Buy" from Brokerages - June 6 at 7:38 AM logoZacks Investment Research Lowers Nevro Corp (NVRO) to Sell - June 3 at 7:12 AM logoRelative Strength Alert For Nevro - May 31 at 7:17 PM logoNevro to Present at the William Blair Growth Stock Conference - May 30 at 6:40 PM logoNevro Corp (NVRO) Downgraded by ValuEngine to Sell - May 24 at 3:56 PM logoZacks: Analysts Anticipate Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million - May 17 at 12:02 PM logoNevro Corp (NVRO) CFO Sells $564,750.00 in Stock - May 16 at 7:33 PM logo-$0.28 EPS Expected for Nevro Corp (NVRO) This Quarter - May 15 at 9:24 AM logoB. Riley Downgrades Nevro Corp (NVRO) to Neutral - May 14 at 10:16 AM logoNevro Corp (NVRO) Given Consensus Recommendation of "Buy" by Brokerages - May 12 at 7:40 AM logoNevro Corp (NVRO) Stock Rating Lowered by Zacks Investment Research - May 11 at 8:04 AM logoEdited Transcript of NVRO earnings conference call or presentation 8-May-17 8:30pm GMT - May 10 at 11:59 AM logoOversold Conditions For Nevro (NVRO) - May 9 at 6:32 PM logoNevro Corp. Just Tumbled By As Much As 12% -- Here's Why - May 9 at 6:32 PM logoMedtech Player Losses Double That Of Views; Shares Tumble - May 9 at 6:32 PM logoNevro Corp (NVRO) Releases Quarterly Earnings Results, Misses Expectations By $0.24 EPS - May 9 at 4:02 PM logoNevro Corp (NVRO) Rating Reiterated by Northland Securities - May 9 at 11:32 AM logoB. Riley Downgrades Nevro Corp (NVRO) to Neutral Citing Slower US-Based Revenue Growth - May 9 at 11:26 AM logoNevro Reports First Quarter 2017 Financial Results - May 8 at 6:23 PM logoNevro reports 1Q loss - May 8 at 4:34 PM logoMedical Product Q1 Earnings on May 8: ITGR, OPK & More - May 5 at 7:13 PM logoNevro Corp (NVRO) Receives Media Impact Score of -0.08 - May 4 at 12:08 PM logoRami Elghandour Sells 10,000 Shares of Nevro Corp (NVRO) Stock - May 3 at 7:00 PM logoMichael F. Demane Sells 29,800 Shares of Nevro Corp (NVRO) Stock - May 3 at 6:56 PM logoNevro to Present at the Bank of America Merrill Lynch 2017 Health Care Conference - Yahoo Finance - May 2 at 4:44 PM



Nevro Corp. (NVRO) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff